Adara Bio Advances R&D Pipeline: Signs Strategic Collaboration Agreement with TFBS Bioscience at Bio Asia–Taiwan 2026
- Adara Bio
- Jul 20
- 2 min read
July 17, 2026
MELBOURNE, AUSTRALIA / TAIPEI, TAIWAN — Melbourne based Adara Bio which is building the next generation of retinal genetic medicines through a programmable RNA editing platform today announced a collaboration with viral vector manufacturer TFBS Bioscience to support its pre-clinical research.
The agreement, finalized during the Bio Asia–Taiwan 2026 conference in Taipei, marking a pivotal milestone in Adara Bio’s research and development timeline, securing high-quality manufacturing infrastructure to accelerate its therapeutic pipeline.
Advancing RNA Base Editing for Inherited Retinal Diseases
Adara Bio’s core mission is the development of life-changing gene therapies utilizing its innovative RNA Base Editing Platform. The platform focuses on correcting mutations responsible for inherited retinal diseases (IRDs), aiming to restore vision and offer durable therapeutic solutions to patients facing degenerative blindness.
“Adara Bio looks forward to leveraging its proprietary gene therapy platform to help restore sight for patients with inherited retinal diseases," said Mr. Jitto Arulampalam, Chairman of Adara Bio. "We are pleased to partner with TFBS Bioscience, a professional CDMO, and believe this collaboration will help accelerate the commercialization of Adara Bio’s gene therapy products, enabling us to bring meaningful benefits to patients sooner.”
The partnership with TFBS Bioscience provides a scalable, specialized manufacturing framework necessary to transition these targeted RNA therapies to support its pre-clinical research.
"We are delighted to collaborate with Adara Bio," added Dr. Tatung Yuan, Chairman and Chief Executive Officer of TFBS Bioscience. "Leveraging TFBS's advanced gene therapy CDMO capabilities and manufacturing capacity, we are committed to supporting the development of this potentially transformative therapy and accelerating its path toward clinical application for the benefit of patients worldwide."
Representatives from Adara Bio and the CERA research team engaged with several of Asia’s leading clinical and scientific networks, touring facilities at National Taiwan University Hospital and Academia Sinica.
The delegation was also honored with an executive meeting with Dr. Chien-Jen Chen, President of Academia Sinica, highlighting the growing synergy and collaborative infrastructure being built between the Australian and Taiwanese biotechnology sectors.
By bridging world-class Australian vision research with Taiwan’s cutting-edge advanced manufacturing capabilities, Adara Bio is uniquely positioned to fast-track its pipeline and bring clinical-stage hope to patients suffering from vision loss globally.
Comments